Published in Br J Pharmacol on March 01, 2011
The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential. Pharmacol Rev (2015) 1.38
Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets? Curr Mol Pharmacol (2015) 0.81
Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch (1981) 134.60
From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron (2000) 9.51
Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature (1983) 5.80
International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev (2005) 5.25
Sequence and expression of mRNAs encoding the alpha 1 and alpha 2 subunits of a DHP-sensitive calcium channel. Science (1988) 3.38
Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol (1997) 2.06
Interactions of organic calcium channel antagonists with calcium channels in single frog atrial cells. J Gen Physiol (1985) 2.04
Limitations of the whole cell patch clamp technique in the control of intracellular concentrations. Biophys J (1990) 1.90
Does the organic calcium channel blocker D600 act from inside or outside on the cardiac cell membrane? Pflugers Arch (1982) 1.90
Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2+ channels. J Clin Invest (2004) 1.69
Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol Sci (1998) 1.69
Pharmacology, structure and function of cardiac L-type Ca(2+) channels. Cell Physiol Biochem (1999) 1.56
Impaired insulin secretion and glucose tolerance in beta cell-selective Ca(v)1.2 Ca2+ channel null mice. EMBO J (2003) 1.51
Block of L-type calcium channels by charged dihydropyridines. Sensitivity to side of application and calcium. J Gen Physiol (1991) 1.24
Calcium channel antagonists: clinical uses--past, present and future. Biochem Pharmacol (2007) 1.23
Dihydropyridine receptor of L-type Ca2+ channels: identification of binding domains for [3H](+)-PN200-110 and [3H]azidopine within the alpha 1 subunit. Proc Natl Acad Sci U S A (1991) 1.16
Transfer of high sensitivity for benzothiazepines from L-type to class A (BI) calcium channels. J Biol Chem (1996) 1.10
Structural determinants of L-type channel activation in segment IIS6 revealed by a retinal disorder. J Biol Chem (2005) 1.10
Molecular determinants of diltiazem block in domains IIIS6 and IVS6 of L-type Ca(2+) channels. Mol Pharmacol (2000) 0.97
Alternative splicing modulates diltiazem sensitivity of cardiac and vascular smooth muscle Ca(v)1.2 calcium channels. Br J Pharmacol (2010) 0.95
Molecular mechanism of diltiazem interaction with L-type Ca2+ channels. J Biol Chem (1998) 0.94
Probing the architecture of an L-type calcium channel with a charged phenylalkylamine: evidence for a widely open pore and drug trapping. J Biol Chem (2006) 0.93
Cardiovascular protection by Ca antagonists. Eur Heart J (1980) 0.91
Sequence differences between alpha1C and alpha1S Ca2+ channel subunits reveal structural determinants of a guarded and modulated benzothiazepine receptor. J Biol Chem (1999) 0.90
Extra- and intracellular action of quaternary devapamil on muscle L-type Ca(2+)-channels. Br J Pharmacol (1996) 0.90
Molecular modeling of benzothiazepine binding in the L-type calcium channel. J Biol Chem (2008) 0.89
Extracellular localization of the benzothiazepine binding domain of L-type Ca2+ channels. Mol Pharmacol (1993) 0.88
A region in IVS5 of the human cardiac L-type calcium channel is required for the use-dependent block by phenylalkylamines and benzothiazepines. J Biol Chem (1999) 0.87
Molecular determinants of Ca2+ potentiation of diltiazem block and Ca2+-dependent inactivation in the pore region of cav1.2. Mol Pharmacol (2003) 0.84
pH-dependent block of the L-type Ca2+ channel current by diltiazem in human mesenteric arterial myocytes. Eur J Pharmacol (1998) 0.79
The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology (2011) 2.06
Use of X-linked markers for forensic purposes. Int J Legal Med (2003) 1.91
Structural basis of drug binding to L Ca2+ channels. Trends Pharmacol Sci (1998) 1.69
Molecular determinants of inactivation and G protein modulation in the intracellular loop connecting domains I and II of the calcium channel alpha1A subunit. Proc Natl Acad Sci U S A (1997) 1.61
Transfer of 1,4-dihydropyridine sensitivity from L-type to class A (BI) calcium channels. Neuron (1996) 1.46
16 X-chromosome STR loci frequency data from a German population. Forensic Sci Int (2001) 1.44
Familial hemiplegic migraine mutations change alpha1A Ca2+ channel kinetics. J Biol Chem (1998) 1.44
Pharmacological properties of GABAA receptors containing gamma1 subunits. Mol Pharmacol (2005) 1.32
Endogenous calcium channels in human embryonic kidney (HEK293) cells. Br J Pharmacol (1996) 1.31
Molecular determinants of inactivation in voltage-gated Ca2+ channels. J Physiol (2000) 1.30
Automated fast perfusion of Xenopus oocytes for drug screening. Pflugers Arch (2006) 1.30
State dependent dissociation of HERG channel inhibitors. Br J Pharmacol (2007) 1.27
The action of caffeine on inward barium current through voltage-dependent calcium channels in single rabbit ear artery cells. Pflugers Arch (1990) 1.25
Modulation of the cloned skeletal muscle L-type Ca2+ channel by anchored cAMP-dependent protein kinase. J Neurosci (1997) 1.23
Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology (2007) 1.15
Characterization of the fast sodium current in isolated rat myocardial cells: simulation of the clamped membrane potential. J Physiol (1982) 1.14
Immortalization and transformation of human fibroblasts by regulated expression of polyoma virus T antigens. Oncogene (1990) 1.14
Ca2+ channel block and inactivation: common molecular determinants. Trends Pharmacol Sci (1998) 1.14
Signaling from beta-adrenoceptor to L-type calcium channel: identification of a novel cardiac protein kinase A target possessing similarities to AHNAK. FASEB J (1999) 1.11
[Interrelations of the processes of sodium activation and inactivation]. Biull Eksp Biol Med (1973) 1.09
Analysis of the dihydropyridine receptor site of L-type calcium channels by alanine-scanning mutagenesis. J Biol Chem (1997) 1.07
[Theoretical analysis of the mechanisms of nerve impulse propagation along a nonuniform axon. I. Propagation along a region with an increased diameter]. Biofizika (1970) 1.04
Modulation of slow inactivation in class A Ca2+ channels by beta-subunits. J Physiol (2000) 1.04
Inactivation determinants in segment IIIS6 of Ca(v)3.1. J Physiol (2001) 1.02
Nine L-type amino acid residues confer full 1,4-dihydropyridine sensitivity to the neuronal calcium channel alpha1A subunit. Role of L-type Met1188. J Biol Chem (1997) 1.02
Molecular mechanism of use-dependent calcium channel block by phenylalkylamines: role of inactivation. Proc Natl Acad Sci U S A (1997) 1.00
Patch-voltage-clamp method for measuring fast inward current in single rat heart muscle cells. Pflugers Arch (1982) 1.00
Sodium and calcium currents in neuroblastoma x glioma hybrid cells before and after morphological differentiation by dibutyryl cyclic AMP. Gen Physiol Biophys (1985) 0.99
Valerenic acid derivatives as novel subunit-selective GABAA receptor ligands - in vitro and in vivo characterization. Br J Pharmacol (2010) 0.99
High affinity interaction of mibefradil with voltage-gated calcium and sodium channels. Br J Pharmacol (2000) 0.97
A light stabilizer (Tinuvin 770) that elutes from polypropylene plastic tubes is a potent L-type Ca(2+)-channel blocker. Proc Natl Acad Sci U S A (1993) 0.97
Block of P/Q-type calcium channels by therapeutic concentrations of aminoglycoside antibiotics. Biochemistry (1996) 0.96
Two amino acid residues in the IIIS5 segment of L-type calcium channels differentially contribute to 1,4-dihydropyridine sensitivity. J Biol Chem (1996) 0.95
The third-generation P-glycoprotein inhibitor tariquidar may overcome bacterial multidrug resistance by increasing intracellular drug concentration. J Antimicrob Chemother (2011) 0.95
Expression of calcium channel subunits in the normal and diseased human myocardium. J Mol Med (Berl) (1996) 0.94
Molecular mechanism of diltiazem interaction with L-type Ca2+ channels. J Biol Chem (1998) 0.94
Characterization of the calcium channel state transitions induced by the enantiomers of the 1,4-dihydropyridine Sandoz 202 791 in neonatal rat heart cells. A nonmodulated receptor model. Pflugers Arch (1989) 0.92
Molecular mechanism of calcium channel block by isradipine. Role of a drug-induced inactivated channel conformation. J Biol Chem (2000) 0.92
Air quality measurements from the Fresno Supersite. J Air Waste Manag Assoc (2000) 0.91
Trapping and dissociation of propafenone derivatives in HERG channels. Br J Pharmacol (2011) 0.90
Sequence differences between alpha1C and alpha1S Ca2+ channel subunits reveal structural determinants of a guarded and modulated benzothiazepine receptor. J Biol Chem (1999) 0.90
Extra- and intracellular action of quaternary devapamil on muscle L-type Ca(2+)-channels. Br J Pharmacol (1996) 0.90
Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines. Mol Pharmacol (1996) 0.88
Nerve impulse propagation along nonuniform fibres. Prog Biophys Mol Biol (1975) 0.88
Amino acids in segment IVS6 and beta-subunit interaction support distinct conformational changes during Ca(v)2.1 inactivation. J Biol Chem (2001) 0.88
Transfer of L-type calcium channel IVS6 segment increases phenylalkylamine sensitivity of alpha1A. J Biol Chem (1996) 0.88
Stimulation of cell division and fibroblast focus formation by antisense repression of retinoblastoma protein synthesis. Oncogene (1992) 0.88
Chimeric L-type Ca2+ channels expressed in Xenopus laevis oocytes reveal role of repeats III and IV in activation gating. J Physiol (1995) 0.86
Mechanism of voltage- and use-dependent block of class A Ca2+ channels by mibefradil. Br J Pharmacol (1998) 0.86
Modulation of calcium channels in arterial smooth muscle cells by dihydropyridine enantiomers. J Gen Physiol (1993) 0.86
Voltage clamp method on single cardiac cells from adult rat heart. Experientia (1980) 0.86
Use- and voltage-dependent depression by ethmozine (moricizine) of the rapid inward sodium current in single rat ventricular muscle cells. J Cardiovasc Pharmacol (1986) 0.85
Molecular basis of drug interaction with L-type Ca2+ channels. J Bioenerg Biomembr (1998) 0.85
Sodium current in freshly isolated and in cultured single rat myocardial cells: frequency and voltage-dependent block by mexiletine. J Mol Cell Cardiol (1983) 0.84
Estimating the efficiency of benzodiazepines on GABA(A) receptors comprising gamma1 or gamma2 subunits. Br J Pharmacol (2008) 0.84
Improved micro-perfusion chamber for multiple and rapid solution exchange in adherent single cells. Pflugers Arch (1995) 0.84
Cloning and functional expression of a neuronal calcium channel beta subunit from house fly (Musca domestica). J Biol Chem (1994) 0.84
Evidence for an external location of the dihydropyridine agonist receptor site on smooth muscle and skeletal muscle calcium channels. Br J Pharmacol (1993) 0.83
Evidence that agonist and antagonist enantiomers of the dihydropyridine PN 202-791 act at different sites on the voltage-dependent calcium channel of vascular muscle. Br J Pharmacol (1990) 0.83
Short-term temporal variation in PM2.5 mass and chemical composition during the Atlanta Supersite Experiment, 1999. J Air Waste Manag Assoc (2003) 0.83
Combined transplantation of skeletal myoblasts and bone marrow stem cells for myocardial repair in rats. Eur J Cardiothorac Surg (2004) 0.82
Characterization of naturally occurring myosin heavy chain antisense mRNA in rat heart. J Cell Biochem (1998) 0.82
On the role of Ca(2+)- and voltage-dependent inactivation in Ca(v)1.2 sensitivity for the phenylalkylamine (-)gallopamil. Circ Res (2001) 0.82
A kinetic analysis of the inward calcium current in 108CC15 neuroblastoma x glioma hybrid cells. Gen Physiol Biophys (1985) 0.81
Inactivation determinant in the I-II loop of the Ca2+ channel alpha1-subunit and beta-subunit interaction affect sensitivity for the phenylalkylamine (-)gallopamil. J Physiol (1999) 0.81
[Stem cell therapy for urinary incontinence]. Urologe A (2004) 0.81
A comparative study of three different biomaterials in the engineering of skeletal muscle using a rat animal model. Biomaterials (2004) 0.81
Mitochondrial DNA in the Central European population. Human identification with the help of the forensic mt-DNA D-loop-base database. Forensic Sci Int (2000) 0.80
Antitumor effects of 3,3',4,4',5,5'-hexahydroxystilbene in HL-60 human promyelocytic leukemia cells. Nucleosides Nucleotides Nucleic Acids (2006) 0.80
Calcium channel block by (-)devapamil is affected by the sequence environment and composition of the phenylalkylamine receptor site. Biophys J (1997) 0.80
[Nerve impulse conduction from the myelinated portion of the axon to the nonmyelinated terminal]. Biofizika (1975) 0.79
[Theoretical analysis of the mechanisms of nerve impulse conduction along a non-uniform axon. II. Conduction of a single impulse through a fiber region with variable functional properties]. Biofizika (1970) 0.79
Voltage-dependent acceleration of Ca(v)1.2 channel current decay by (+)- and (-)-isradipine. Br J Pharmacol (2001) 0.78
X chromosomal and autosomal loss of heterozygosity and microsatellite instability in human cervical carcinoma. Int J Gynecol Cancer (2006) 0.78
Methods for quantification of pore-voltage sensor interaction in Ca(V)1.2. Pflugers Arch (2013) 0.78
[Theoretical analysis of the mechanisms of nerve impulse propagation along a nonuniform axon. IV. Propagation of series of impulses through the fiber region with enlarged diameter]. Biofizika (1971) 0.78
[35S]sadopine, a novel high affinity, high specific activity, L-type Ca2+ channel probe: characterization of two equipotent diastereomers with opposite allosteric properties. Mol Pharmacol (1992) 0.77
Resveratrol, an ingredient of wine, acts synergistically with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Nucleosides Nucleotides Nucleic Acids (2006) 0.77
[Investigations on the endoparasitic fauna of domestic cats in eastern Brandenburg]. Berl Munch Tierarztl Wochenschr (1997) 0.77
A method for estimation of drug affinity constants to the open conformational state of calcium channels. Biophys J (1992) 0.77
[Airway manifestations of relapsing polychondritis: treatment with cyclophosphamide and placement of bronchial stents]. Z Rheumatol (2003) 0.76
On the fate of skeletal myoblasts in a cardiac environment: down-regulation of voltage-gated ion channels. J Physiol (2004) 0.76
Responses to noradrenaline of tail arteries in hypertensive, hypotensive and normotensive rats under different regimens of perfusion: role of the myogenic response. Acta Physiol Scand (1998) 0.76
TNFa and b microsatellites in Germany. Int J Legal Med (1998) 0.76
[Free fatty acids in the serum in critical diseases: do they play a role in the protein binding of thyroid hormones?]. Klin Wochenschr (1988) 0.75
The role of purinergic and adrenergic transmitters of the sympathetic system in the control of arterial blood pressure variability. J Auton Nerv Syst (1998) 0.75
Comments on the paper entitled "polymorphism of nine X chromosomal STR loci in Koreans" by Jin Young Son et al. (2002) Int J Legal Med 116:317-321. Int J Legal Med (2003) 0.75
Thyroid hormone binding inhibition in critically ill patients--who is the inhibitor? Exp Clin Endocrinol (1990) 0.75